Mineralys Therapeutics, Inc.
NASDAQ:MLYSBiotechnology
+$0.37 today
- Market cap
- $1.22B
- Beta
- 0.56
- P/E (TTM)
- -13.9
- EPS (TTM)
- -$1.83
Volume 1.39M
Average 1.48M
MLYS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Mineralys Therapeutics, Inc.NASDAQ: MLYS
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development growth accelerates
Q2 FY2026 research & development of $221.38M rose 478.3% year over year, ahead of the +72.6% change in trailing-twelve-month research & development. Sequentially, it rose 808.6% from the prior quarter. Over 3 fiscal years it compounded at +71.3% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +478.3% holds above the trailing-twelve-month pace of +72.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 132.01M USD
- Year-over-year change
- -21.7%
- 4-year CAGR
- +68.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 132.01M | -21.7% |
| FY2024 | 2024-12-31 | 168.58M | +139.6% |
| FY2023 | 2023-12-31 | 70.36M | +168.0% |
| FY2022 | 2022-12-31 | 26.25M | +61.0% |
| FY2021 | 2021-12-31 | 16.31M | — |
Research & Development vs competitors
How MLYS compares with its peers on the latest reported figures
- MLYS's LTM Jun 2026 research & development of $301.59M is the highest of the 7 companies compared; the peer median is $87.53M.
- Its year-over-year change of +72.6% is the highest of 7, against a peer median of +28.1%.
- Over three fiscal years its annual growth of +71.3% compares with a peer median of +22.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $301.59M | +72.6% | +71.3% | — | |
| LTM Jun 2026 | $261.87M | +51.3% | +45.5% | — | |
| LTM Sep 2026 | $245.55M | +16.8% | -3.2% | 37.7% | |
| LTM Mar 2026 | $114.57M | +28.4% | +7.1% | 572.9% | |
| LTM Mar 2026 | $60.48M | +28.2% | +38.4% | 184.8% | |
| LTM Mar 2026 | $26.95M | +28.1% | +46.4% | — | |
| LTM Mar 2026 | $8.57M | -44.2% | -9.8% | — | |
| Peer median (excluding MLYS) | $87.53M | +28.1% | +22.8% | 184.8% | |
Competitors are the stored peer set for MLYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 16.31M | 26.25M | 70.36M | 168.58M | 132.01M |
| Selling, General & Admin | 2.42M | 5.23M | 14.3M | 23.82M | 38.6M |
| Operating Expenses | 18.73M | 31.48M | 84.66M | 192.4M | 170.6M |
| Depreciation & Amortization | 0 | 0 | 0 | 43K | 59K |
| EBITDA | (19.38M) | (28.12M) | (71.9M) | (177.77M) | (154.59M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (18.73M) | (31.48M) | (84.66M) | (192.4M) | (170.6M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 1.68M | 12.76M | 14.59M | 15.95M |
| Interest Expense | 27K | 1.68M | 0 | 0 | 0 |
| Other Income / Expenses | (683K) | 1.68M | 12.76M | 14.59M | 15.95M |
| Income Before Tax | (19.41M) | (29.8M) | (71.9M) | (177.81M) | (154.65M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (19.41M) | (29.8M) | (71.9M) | (177.81M) | (154.65M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (3.89) | (5.77) | (1.99) | (3.66) | (2.29) |
| EPS (Diluted) | (3.89) | (5.77) | (1.99) | (3.66) | (2.29) |
| Weighted Avg Shares | 4.98M | 5.17M | 36.19M | 48.54M | 67.66M |
| Weighted Avg Shares (Diluted) | 4.98M | 5.17M | 36.19M | 48.54M | 67.66M |
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
Intrinsic Alpha fair value
Locked
Current Price
$13.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.